Positive impactCompany
Jefferies initiates coverage on Anthem Biosciences with a Rs 1,050 target
Economic Times 1 hr ago·21 Aug 2026, 5:19 am
Jefferies Financial Group has initiated coverage on Anthem Biosciences with a Buy rating and a target price of Rs 1,050. This valuation implies a potential upside of approximately 20% for investors. The brokerage firm views the company favorably due to its integrated Contract Research, Development, and Manufacturing Organization (CRDMO) business model, which allows it to offer a full spectrum of services to pharmaceutical clients.
This positive outlook is supported by Anthem’s strong return ratios and expected revenue growth, with Jefferies forecasting an 18% compound annual growth rate through fiscal year 2029. The firm cites the company’s pipeline of new commercial molecules and biosimilar launches as key growth drivers. However, investors should remain mindful of the risks associated with high capital expenditure and customer concentration.
Affected stocks
Bullish1 stock
Bull / bear label is derived from the article's AI sentiment — indicative, not advice. Prices may be delayed.
Key takeaways
- Concerns Anthem Biosciences (ANTHEM).
- Category: Company.
- AI reads the tone as positive (potentially bullish) for the stock.
- Assessed as a significant, market-relevant update.
Why it matters
A meaningful update for Anthem Biosciences worth tracking. The tone is positive — historically associated with upward pressure, though not predictive. Use the price and stock snapshot to gauge how the market is responding.
